NASDAQ:IMRA IMARA (IMRA) Stock Price, News & Analysis → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free IMRA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$6.32▼$25.2852-Week Range N/AVolume271,700 shsAverage Volume138,364 shsMarket Capitalization$165.80 millionP/E Ratio126.40Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get IMARA alerts: Email Address Ad Weiss Ratings[URGENT] DO NOT Touch These AI Stocks!Artificial intelligence stocks are carrying the market. One of them, Nvidia, recently became the seventh company ever to hit a $1 trillion market cap. But is this AI rally over?Click here for our #1 AI Stock for 2024 and Beyond About IMARA Stock (NASDAQ:IMRA)IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2-related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Read More Ad Weiss Ratings[URGENT] DO NOT Touch These AI Stocks!Artificial intelligence stocks are carrying the market. One of them, Nvidia, recently became the seventh company ever to hit a $1 trillion market cap. But is this AI rally over?Click here for our #1 AI Stock for 2024 and Beyond IMRA Stock News HeadlinesAugust 23, 2023 | health.usnews.comImara BlumeMarch 3, 2023 | finance.yahoo.comIMARA Inc. (IMRA) Stock Historical Prices & Data - Yahoo FinanceMay 8, 2024 | Manward Press (Ad)Shocking: One AI startup's revenue could surge 4,735%Shocking: One AI Startup's Revenue Could Surge 4,735% While Nvidia gets all the attention, one small AI startup is quietly positioning itself to be the biggest winner.February 22, 2023 | finance.yahoo.comImara Announces Stockholder Approval of Merger With EnlivenJanuary 5, 2023 | benzinga.comSHAREHOLDER ALERT: Weiss Law Reminds IMRA, TIG, FORG, and BRBW Shareholders About Its Ongoing InvestigationsOctober 25, 2022 | benzinga.comImara 10% Owner Trades $336K In Company StockOctober 20, 2022 | benzinga.com$1.9 Million Bet On This Biotechnology Stock? Check Out These 4 Penny Stocks Insiders Are Buying - Imara - BenzingaOctober 18, 2022 | prnewswire.comSTOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of IMARA Inc. - IMRA - PR NewswireMay 8, 2024 | Manward Press (Ad)Shocking: One AI startup's revenue could surge 4,735%Shocking: One AI Startup's Revenue Could Surge 4,735% While Nvidia gets all the attention, one small AI startup is quietly positioning itself to be the biggest winner.October 18, 2022 | prnewswire.comSTOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of IMARA Inc. - IMRAOctober 17, 2022 | streetinsider.comAHF to Protest CIGNA for Shortchanging Pharmacies: 'Cigna Doesn't Care!' - StreetInsider.comOctober 17, 2022 | bloomberg.comZimbabwe's Currency Crackdown Spurs Wider Use of US Dollars - BloombergOctober 17, 2022 | bizjournals.comStruggling blood disorder biotech Imara shuts down via reverse merger - Boston Business Journal - The Business JournalsOctober 17, 2022 | benzinga.com12 Health Care Stocks Moving In Monday's Pre-Market Session - Applied DNA Sciences (NASDAQ:APDN), Acorda - BenzingaOctober 16, 2022 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LOGC, FCRD, IMRA - Imara (NASDAQ:IMRA), First Ea - BenzingaOctober 15, 2022 | benzinga.comLifshitz Law PLLC Announces Investigations of OIIM, JVA, SLDB, and IMRA - Imara (NASDAQ:IMRA), Coffee Hol - BenzingaOctober 15, 2022 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LOGC, IMRA, SBTX - Imara (NASDAQ:IMRA), LogicBio - BenzingaOctober 14, 2022 | benzinga.comHow Is The Market Feeling About Imara? - Imara (NASDAQ:IMRA) - BenzingaOctober 14, 2022 | morningstar.co.ukArix Bioscience says Imara to merge with Enliven Therapeutics - MorningstarOctober 14, 2022 | prnewswire.comThinking about buying stock in Imara, Nutanix, Azul, 22nd Century Group, or Altimmune? - PR NewswireOctober 14, 2022 | benzinga.comWhy IMARA Shares Are Trading Higher By Over 13%; Here Are 22 Stocks Moving Premarket - Black Diamond Ther - BenzingaOctober 14, 2022 | marketscreener.comIMARA INC. : Other Events, Financial Statements and Exhibits (form 8-K) - Marketscreener.comOctober 13, 2022 | ca.investing.comDow Futures Tick Higher After Indices Stage Major Reversal By Investing.com - Investing.com CanadaOctober 13, 2022 | seekingalpha.comCancer drug developer Enliven Therapeutics and Imara to merge in all-stock deal - Seeking AlphaOctober 13, 2022 | streetinsider.comForm 8-K IMARA Inc. For: Oct 13 - StreetInsider.comOctober 13, 2022 | marketwatch.comImara, Enliven Therapeutics Agree to Merge in All-Stock Deal - MarketWatchOctober 13, 2022 | businesswire.comIMRA Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Imara Inc. is Fair to Shareholders - Business WireSee More Headlines Receive IMRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IMARA and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMRA CUSIPN/A CIK1672619 Webwww.imaratx.com PhoneN/AFaxN/AEmployees41Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.05 Trailing P/E Ratio126.40 Forward P/E RatioN/A P/E GrowthN/ANet Income$1.49 million Net MarginsN/A Pretax MarginN/A Return on Equity2.12% Return on Assets2.00% Debt Debt-to-Equity RatioN/A Current Ratio48.98 Quick Ratio48.98 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash Flow75.24 Book Value$3.44 per share Price / BookN/AMiscellaneous Outstanding Shares26,234,000Free Float16,449,000Market Cap$165.80 million OptionableNot Optionable Beta1.09 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Rahul D. Ballal Ph.D. (Age 44)Pres, CEO & Director Comp: $761.55kMr. Michael P. Gray MBA (Age 51)CPA, CFO & COO Comp: $641.24kMr. Stephen M. Migausky J.D.Sr. VP of Legal & Gen. CounselKey CompetitorsInventivaNASDAQ:IVACapricor TherapeuticsNASDAQ:CAPRscPharmaceuticalsNASDAQ:SCPHGossamer BioNASDAQ:GOSSGreenwich LifeSciencesNASDAQ:GLSIView All Competitors IMRA Stock Analysis - Frequently Asked Questions How were IMARA's earnings last quarter? IMARA Inc. (NASDAQ:IMRA) released its quarterly earnings data on Tuesday, November, 9th. The company reported ($2.20) EPS for the quarter, topping the consensus estimate of ($3.64) by $1.44. During the same period in the previous year, the company earned ($2.88) EPS. When did IMARA's stock split? IMARA shares reverse split on Friday, February 24th 2023. The 1-4 reverse split was announced on Friday, February 24th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. What other stocks do shareholders of IMARA own? Based on aggregate information from My MarketBeat watchlists, some companies that other IMARA investors own include Novavax (NVAX), Axsome Therapeutics (AXSM), OPKO Health (OPK), BioXcel Therapeutics (BTAI), Johnson & Johnson (JNJ), Bristol-Myers Squibb (BMY), Dynavax Technologies (DVAX), Micron Technology (MU), Provention Bio (PRVB) and Abbott Laboratories (ABT). When did IMARA IPO? IMARA (IMRA) raised $76 million in an IPO on Thursday, March 12th 2020. The company issued 4,500,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Citigroup and SVB Leerink served as the underwriters for the IPO. This page (NASDAQ:IMRA) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorAI “wealth window” is closing June 25thParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsStock-Picking AI Predicts #1 Stock of 2024AltimetryElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyThe AI Stock that’s Disrupting Every IndustryStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMARA Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.